SBI-0206965, 5 mg

STEMCELL Technologies offers SBI-0206965 as a small molecule inhibitor targeting the autophagy initiator kinases ULK1 and ULK2, with reported IC50 values of 108 nM and 711 nM, respectively. The compound also acts as a potent inhibitor of AMP-activated protein kinase (AMPK), a positive regulator of autophagy. Its chemical name is 2-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]oxy]-N-methyl-benzamide, and the chemical formula is C21H21BrN4O5.

In published cancer research applications, SBI-0206965 has been shown to synergize with mTOR inhibition to induce apoptosis and cell death in tumor cells, suppress autophagy induced by mTOR inhibition, and suppress prosurvival autophagic responses in tumor cells through AMPK and ULK1 inhibition.

The product is supplied as a crystalline solid with a purity of ≥ 98%. It is stable at -20°C as supplied and should be protected from prolonged exposure to light; for long-term storage, it should be stored with a desiccant. The compound remains stable as supplied for 12 months from the date of receipt. Reported solubility limits are ≤ 60 mM in DMSO and ≤ 2.0 mM in absolute ethanol, and the compound has low solubility in aqueous media. For use as a cell culture supplement, the stock solution should be diluted into culture medium immediately before use, with final DMSO concentration kept below 0.1% to avoid potential cell toxicity.